55 -3 (35) 2021 — Shokirova Sadokathon Mukhammatsolievna — MODERN UNDERSTANDING OF POLYCYSTIC OVARIAN SYNDROME

MODERN UNDERSTANDING OF POLYCYSTIC OVARIAN SYNDROME

Shokirova Sadokathon Mukhammatsolievna Department of Obstetrics and Gynecology No.2 Andijan State Medical Institute

Resume,

Polycystic ovarian syndrome (TPS) is one of the urgent problems of obstetrics and gynecology, and this disease occurs in 80% of infertility cases. This disease is a complex multifactorial disease, degenerates with multigenicity and is formed under the influence of environmental factors. More than a thousand genes have been found in all tissues and cells of the ovary, which play an important role in the development of this disease.

To study the etiology and pathogenesis of polycystic ovarian syndrome based on genetic tests, which leads to improved diagnosis of the disease and individual assessment of risk factors in each patient, preventive and therapeutic methods are predicted.

Key words: ovaries, infertility, polycystic, multigenital, expression.

First page

279

Last page

282

For citation: Shokirova Sadokathon Mukhammatsolievna MODERN UNDERSTANDING OF POLYCYSTIC OVARIAN SYNDROME//New Day in Medicine 3(35)2021 279-282 https://cutt.ly/OEOzmpr

LIST OF REFERENCES:

  1. Lebby I., Temime B.R., Fedlaoi A., Feki A. Ovarian drilling in PCOS: is it really useful? The Front Is Heaving. 2015;2:30.
  2. Erin K. Barthelmess and Rajesh K. Polycystic ovary syndrome Naz: current state and prospects for the future Before Biosci (Eliteed). 2015;6:104-19.
  3. Ozziz R., Woods K.S., Reina R., Ki T.J., Knochenhauer E.S., Star B.O. Prevalence and features of polycystic ovary syndrome in an unselected population. //J. Clinic. Endocrinol. Metab. 2004;89:2745-49.
  4. Merkin S.S., Ozziz R., Siman T., Calderon-Margalit R., Daviglus M., Kif K., Mathews K., Sternfeld B., Siskovik D. Socio-economic status and polycystic ovary syndrome. //J. Women’s health. 2011;20:413-19.
  5. Mohamed-hUssein Z.A. Aaron S. Constructing the pathway of polycystic ovary syndrome (PCOS) based on the interaction of proteins associated with PCOS obtained from bibliomic data. Theor. //This is a BIAL. Med. model. 2009;6:18.
  6. 6.Uvarova E.V., Khatsenko E.P. Polycystic ovary syndrome from the perspective of modern pathogenesis. Reproductive health of children and adolescents. 2013. 7c.
  7. Dushkova M., Chermakova I., Hill M., Vankova M., Samalakova P., Starka L. What are the markers of the male equivalent of polycystic ovary syndrome? Physiol. Usage 2004;53:287-94.
  8. Gur E.B., Karadeniz M., Turan G.A. Fetal programming of polycystic ovary syndrome. The world of S. Diabetes. 2015;6(7):936-42.
  9. Escabar-Morreale iron metabolism and polycystic ovary syndrome. Trends of the endocrine system. Metab. 2012;23(10):509-1.
  10. Irani M., Merhi Z. The role of vitamin D in ovarian physiology and its effect on reproductive function: a systematic look at infertility. 2014;102(2):460-68.
  11. Joseph S., Barei R.S., Focrea R., Idikola-Thomas S. PCOSKB: knowledge base on genes, diseases, ontology terms and biochemical pathways associated with polycystic ovary syndrome. Nucleic Acids, Res. 2016; 44(D1).
  12. Iliadromiti S., Kelsey T.U., Anderson R.A., Nelson S.M. Can the anti-Muller hormone predict the diagnosis of polycystic ovary syndrome? Systematic review and meta-analysis of extracted data. //J. Klin. Endocrinol. Metab. 2013;98(8):3332 40.
  13. Legro R.S., Arslanyan S.A., Ermann D.A., Hoger K.M., Murad M.H., Pasquali R., Welt K.K. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: a guide to the clinical practice of the Endocrine Society. //J. Klin. Endocrinol. Metab. 2013;98(12):4565-92.
  14. Caruso S. Sorry., Malandrino S., Flower., Lo Presti L., Cianci Hyperandrogenic women receiving oral contraceptives of continuous action. //Eur. J. Obstetrics. Gynecol. Reprod. This is BIAL. 2013;171(2):307-10.
  15. Ores R., Arro M., Pani F., Maratta M.F., Pilloni M., Guerriero S., Etzi R., Zedda P., Sorge R., Lello S., Melis G.B., Pauletti A.M. Endocrinological, metabolic and clinical features of treatment with oral contraceptives that continue taking ethinyl estradiol plus chlormadinone acetate in non-obese women with polycystic ovary syndrome. //Contraception. 2010;82(2):131-38.
  16. Angstwurm M.U., Gartner R., Ziegler-Heitbrok H.U. Levels of IL-6 in blood plasma during the normal menstrual cycle. Cytokine. 1997;9:370-74.
  17. Petrikova J., Lazurowa I., Yehuda S. polycystic ovary Syndrome and autoimmunity. //Eur. J. Intern. Med. 2010;21:369-71.
  18. Ilie R. I. Marian I., Masan T., Elijah R., Mahan, L., Dana I., S. E. Pepin Этинилэстрадиол30 Mcgrenere and Metformin: can this combination to improve endothelial dysfunction in polycystic ovary syndrome? BMC endocrinologist. Disord. 2012;12:9.
  19. Barry S.A., Azizia M.M., Hardiman P.J. The risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. This is a Drone. Reprod. Update. 2014;20(5):748-58.
  20. Shindler A.E. Non-contraceptive advantages of oral hormonal contraceptives // Endocrinol. Metab. 2013;11(1):41-7.-7.

file

download